在预测肝细胞癌的治疗点中HOTAIR表达试验的价值:元分析和生物信息学分析
Ping Wen1, Xiyu Qi2, Ruzhen Zheng3
1Department of Second Stationed Out-Patient, General Hospital of Northern Theatre Command, Wenhua Road 83, Shenyang, Liaoning 110068, P.R. China.
The International journal of biological markers
|May 15, 2024
概括
长非编码RNAHOTAIR的高表达与晚期肝细胞癌 (HCC) 和患者生存率低下有关. 霍泰尔可以作为一个有价值的生物标志物来预测HCC的进展和结果.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 长非编码RNAHOTAIR在各种癌症中被上调.
- 它在肝细胞癌 (HCC) 预后中的作用尚未完全理解.
研究的目的:
- 调查HOTAIR和肝细胞癌 (HCC) 之间的关联.
- 评估HOTAIR作为HCC的潜在预后生物标志物.
主要方法:
- 在PubMed,Embase和Web of Science的系统文献综述.
- 八项研究 (399名患者) 的元分析和使用TCGA数据的生物信息分析.
- 使用危险比率和R软件进行统计评估.
主要成果:
- 高HOTAIR表达与晚期HCC阶段,转移和差异化相关.
- 在HCC患者中,HOTAIR与总体和无复发生存率的降低有关.
- 生物分析证实HCC的HOTAIR较高,其与生存率差和TNM晚期的关联.
结论:
- 霍泰尔显示出作为HCC.预测生物标志物的潜力.
- 它可能为临床HCC预测和预后提供一个新的选择.
相关概念视频
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
02:39lncRNA - Long Non-coding RNAs
8.6K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K